Molbio Diagnosti — 360° view

Molbio Diagnosti, a company in the Medical Equipment & Supplies industry, reported revenue of ₹249 crore and net profit of ₹31 crore for the September 2026 quarter.

Molbio Diagnosti (NSE: MOLBIO) closed at ₹1,495.50 on 20 Nov 2026. Its market capitalisation is ₹17,234 crore and it trades at 237.7 times earnings.

Share price
₹1,495.50 (20 Nov 2026)
Market cap
₹17,234 Cr (20 Nov 2026)
P/E
237.68 (20 Nov 2026)
Revenue
₹249 Cr (September 2026 quarter)
Net profit
₹31 Cr (September 2026 quarter)
ROCE
18.0% (FY26)
ROE
13.8% (FY26)
Book value
₹123 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,686.80 / ₹1,012.00 (20 Nov 2026)
Sector
Healthcare
Industry
Medical Equipment & Supplies
Symbol
NSE: MOLBIO

Molbio Diagnostics is an innovative point- of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care. Through its wholly owned subsidiary, Bigtec Labs, Molbio has strong research and development capabilities focused on creating diagnostic platforms for point-of- care (POC) testing. From product development to large-scale deployment, the company aims to improve access to reliable and affordable healthcare for everyone.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.